Orion Market Research
Global DNA Vaccine Market Research and Forecast 2018-2023
Orion Market Research
DNA Vaccine Market DNA vaccines Market are the third generation vaccines that designed to overcome the undesirable properties of conventional vaccines. The increasing exposure of population to infectious diseases and increasing number of antibiotics resistant pathogens have created the need for effective and low-cost vaccination, which would provide long lasting immunity. DNA vaccines have low risk of infection, easy transportation and stability at room temperature and hence are advantageous over traditional vaccines.
Orion Market Research
DNA vaccines target a wide range of traditional pharmaceutical markets, such as cancers and allergies, as well as infectious diseases. The global DNA vaccines market is experiencing rapid growth owing to the factors such adoption of DNA vaccines in healthcare, low costs of DNA vaccines, and increasing investments in DNA technology. The increase in the prevalence of chronic diseases such as cancer, hepatitis, HIV and others are augmenting the growth of the global DNA vaccine market. Moreover, relative ease of large-scale manufacturing compared to traditional approach and less storage requirement are some of the key market drivers.
Orion Market Research
The other factors augmenting the growth of the market includes increasing clinical trials for DNA vaccines both animal based and human based. Several DNA vaccine clinical trials have been recently completed or are currently ongoing, such as ZYC101 (Eisai Pharmaceuticals) has completed phase I trial. HPV-16 and HPV-18 E6/E7 are being evaluated in a phase I clinical trial (Inovio Pharmaceuticals). DNA vaccines have already made significant progress to date. Nearly 100 clinical trials are on-going in humans for a wide range of diseases, and there is a deep pipeline of preclinical projects.
Orion Market Research
However, uncertainty in regulatory policies and less penetration of DNA vaccine technology in the emerging economies is hindering the growth of the market. However, the increasing benefits offered by the DNA based vaccines and increasing awareness will have a positive impact on the growth of the market in the future. The DNA vaccine market is segmented on the basis type, technology and application. On the basis of type, the market is segmented into animal DNA vaccine and human DNA vaccine. On the basis of technology, the market is bifurcated into Plasmid DNA vaccine and plasmid DNA delivery technology.
Orion Market Research
On the basis of application, the market is divided into oncology, infectious diseases and others. The market for oncology based DNA vaccines and Infectious diseases is one of the largest segment for the DNA based vaccines. Clinical trials for DNA vaccines to treat cancer including metastatic melanoma, prostate, and pancreatic cancer, and other solid tumors, are showing promising results. Inovio Pharmaceuticals has also been working on a DNA-based vaccine for Zika since December 2015.
Orion Market Research
The global DNA vaccine market is analysed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America dominates the global DNA vaccine market due to the presence of all the major key pharmaceutical companies and increasing clinical trials. Europe is the second largest market followed by Asia pacific region. Asia pacific is the fastest growing segment due to increasing awareness about the benefits and flexibility offered by DNA vaccines.
Orion Market Research
The companies contributing to the growth of global DNA vaccine market are Astellas Pharma, Bharat Biotech, Dendreon Corporation, Indian Immunologicals Limited, GE Healthcare Life Sciences, GlaxoSmithKline Inc., Green Cross Corporation, Innovio Biomedical Corporation, Pfizer Pharmaceuticals, Sanofi, The Serum Institute of India Pvt. Limited, Zoetis Inc. and so on. US – AgriLabs in November 2017, announced the United States Department of Agriculture (USDA) approval of the first DNA vaccine licensed for chickens.
Orion Market Research
The approval also represents the first for AgriLabs ExactVacTM DNA technology with ENABL adjuvant, the first DNA vaccine approved for influenza for veterinary use, and among the first DNA vaccines approved in the US for food animals.
Orion Market Research
Table Of Content 1. REPORT SUMMARY 1.1. RESEARCH METHODS AND TOOLS 1.2. MARKET BREAKDOWN 1.2.1. BY SEGMENTS 1.2.2. BY GEOGRAPHY 1.2.3. BY STAKEHOLDERS
Orion Market Research
2. MARKET OVERVIEW AND INSIGHTS 2.1. DEFINITION 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS 2.3. REGULATIONS 2.4. PIPELINE ANALYSIS
Orion Market Research
3. MARKET DETERMINANT 3.1. MOTIVATORS 3.2. RESTRAINTS 3.3. OPPORTUNITIES
Orion Market Research
4. MARKET SEGMENTATION 4.1. GLOBAL DNA VACCINE MARKET BY TYPE 4.2. GLOBAL DNA VACCINE MARKET BY TECHNOLOGY 4.3. GLOBAL DNA VACCINE MARKET BY APPLICATION 5. COMPETITIVE LANDSCAPE 5.1.1. KEY COMPANY ANALYSIS 5.1.2. KEY STRATEGY ANALYSIS
Orion Market Research
6. REGIONAL ANALYSIS 6.1. NORTH AMERICA 6.2. EUROPE 6.3. ASIA PACIFIC 6.4. REST OF THE WORLD
Orion Market Research
7. COMPANY PROFILES 7.1. ASTELLAS PHARMA 7.2. BHARAT BIOTECH 7.3. DENDREON CORPORATION 7.4. INDIAN IMMUNOLOGICALS LIMITED 7.5. GE HEALTHCARE LIFE SCIENCES 7.6. GLAXOSMITHKLINE INC. 7.7. GREEN CROSS CORPORATION 7.8. INNOVIO BIOMEDICAL CORPORATION 7.9. IMMUNOMIC THERAPEUTICS 7.10. MERCK & CO.
Orion Market Research
CONTACT US Orion Market Research Pvt. Ltd. (OMR Global) 116, Shagun Arcade, Vijay Nagar Square, Indore, Madhya Pradesh India- 452010
+1-646-755-7667 +91-7803040404 info@omrglobal.com www.omrglobal.com/ https://www.omrglobal.com/industry-reports/dna-vaccines-market/